Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 7, 2010
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, at...
-
Dec 9, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for Clobetasol Propionate Topical Spray, 0.05%, a generic form of Clobex® Spray....
-
Dec 7, 2009Gluten-free labeling program an industry first for over-the-counter pharmaceuticals
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced it will implement a labeling program to help consumers more clearly identify more than 200 of the company's over-the-counter store-brand...
-
Nov 19, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Sidoti Emerging Growth Conference on Friday, November 20, at 3:15 p.m....
-
Nov 9, 2009In the news release, Perrigo Company to Present at the Credit Suisse 18th Annual Health Care Conference, issued 09-Nov-2009 by Perrigo Company over PR Newswire, we are advised by the company that in the first paragraph, the conference date and time should
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse 18th Annual Health Care Conference on Wednesday, November...
-
Nov 9, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the Credit Suisse 18th Annual Health Care Conference on Wednesday, November...
-
Nov 2, 2009
-- Fiscal first quarter revenue from continuing operations increased $72 million, or 16%, to $528 million -- Fiscal first quarter GAAP income from continuing operations increased 59% to $61...
-
Nov 2, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has signed a definitive agreement to sell its Israel Consumer Products business along with the related production assets in...
-
Oct 29, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on December 15, 2009 to shareholders of record on...
-
Oct 19, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 a.m. (ET). The...
-
Oct 19, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the Hatch-Waxman litigation relating to Duac® Gel (clindamycin phosphate (1%) and benzoyl peroxide (5%) gel) filed by the Stiefel...
-
Oct 13, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application for over-the-counter (OTC) Minoxidil topical aerosol foam, 5%, a generic form of...
-
Oct 6, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for...
-
Sep 21, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) will hold its Investor Day from 8:30 a.m. to approximately 12:00 p.m. EDT on September 29, at the NASDAQ MarketSite located at 4 Times Square in New...
-
Sep 21, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has purchased the ANDA for clindamycin phosphate (1%) and benzoyl peroxide (5%) gel from KV Pharmaceutical for $14 million in...
-
Aug 18, 2009- Full-year revenue from continuing operations increased $277 million, or 16 percent, to a record $2 billion - Adjusted income from continuing operations for the full year increased 13 percent to $175 million, or $1.87 per share - GAAP income from continu
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fourth quarter and full year ended June 27, 2009. Perrigo's Chairman and CEO Joseph C. Papa commented, "Our sales topped...
-
Aug 13, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on September 15, 2009 to shareholders of record on...
-
Aug 4, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2009 on Tuesday, August 18, 2009 at approximately 8:00 a.m. (ET). The Company...
-
Aug 3, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) (previously Barr Laboratories Inc.) has received final approval from...
-
Jul 13, 2009
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter coated nicotine polacrilex...
-
Jun 24, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Synthon Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Levocetirizine solution...
-
May 7, 2009
-- Fiscal third quarter revenue from continuing operations increased $25 million, or 5%, to $506 million as compared to $481 million this quarter a year ago -- Fiscal third quarter earnings from...
-
May 6, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on June 16, 2009 to shareholders of record on May...
-
Mar 24, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to market Sulfacetamide Sodium Topical Suspension, 10%...
-
Mar 17, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner Cobrek Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Clindamycin Phosphate Foam 1%, a...
-
Feb 20, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that has begun shipping over-the-counter (OTC) Ibuprofen and Diphenhydramine Citrate Tablets, 200/38 mg. The product will be marketed...
-
Feb 3, 2009- Fiscal second quarter revenue increased $126 million, or 29%, to $561 million as compared to $435 million this quarter a year ago
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2009 second quarter and six months that ended December 27, 2008. Perrigo Company (in thousands, except per...
-
Jan 28, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on March 17, 2009 to shareholders of record on...
-
Jan 21, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal year 2009 on Tuesday, February 3, 2009 at approximately 8:00 a.m....
-
Jan 7, 2009
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12, at...
-
Dec 29, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...
-
Dec 4, 2008
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg) has been settled with Perrigo taking a license under all...
-
Nov 19, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today acknowledges the settlement of patent litigation brought by Sanofi-Aventis (NYSE: SNY) against Barr Laboratories, Inc. a subsidiary of Barr...
-
Nov 13, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired Unico Holdings for approximately $49 million in cash. Based in Lake Worth, Florida, privately-held Unico is the...
-
Nov 6, 2008* Fiscal first quarter revenue of $480 million represents an increase of $97 million, or 25 percent, from first quarter last year
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2009 first quarter that ended September 27, 2008. Perrigo Company (in thousands, except per share amounts)...
-
Nov 4, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on December 16, 2008 to shareholders of record on...
-
Oct 29, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...
-
Oct 23, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal year 2009 on Thursday, November 6, 2008 at approximately 8:00 a.m....
-
Oct 6, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired Laboratorios Diba, S.A. for approximately $25 million in cash. Based in Guadalajara, Mexico, privately-held...
-
Oct 3, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the JMP Securities 2008 Healthcare Focus Conference on Monday, October 6, at...
-
Sep 18, 2008
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the Hatch-Waxman litigation relating to Miconazole Nitrate Vaginal Cream and Suppository between Johnson & Johnson and Perrigo...
-
Sep 16, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired JB Laboratories for approximately $44 million in cash. Based in Holland, Michigan, privately-held JB Laboratories is...
-
Sep 15, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Judy Brown, Perrigo's CFO will present at the Merrill Lynch Global Pharmaceutical Conference on Tuesday, September 16 at the Merrill...
-
Sep 8, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the generic version of UCB's Xyzal®...
-
Aug 18, 2008- Full year revenue increased $375 million, or 26 percent, to a record $1.8 billion, including $500 million for the fourth quarter
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fourth quarter and full year ended June 28, 2008. Perrigo's Chairman and CEO Joseph C. Papa commented, "For the third...
-
Aug 13, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on September 16, 2008 to shareholders of record on...
-
Aug 11, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it began shipping Famotidine Complete chewable tablets (famotidine 10 mg; calcium carbonate 800mg; magnesium hydroxide 165 mg) to...
-
Aug 5, 2008In the release, Perrigo Company to Present at the Bank of America Specialty Pharmaceuticals Conference, issued earlier today by Perrigo Company (Nasdaq: PRGO; TASE), over PR Newswire, we are advised by the Company that the first sentence of the first para
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Judy Brown, Perrigo's Chief Financial Officer, will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday,...
-
Aug 5, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday,...
-
Aug 5, 2008
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2008 on Monday, August 18, 2008 at approximately 8:00 a.m. (ET). The Company...